Mirum Pharmaceuticals MIRM 深 滬
已收盤 02-06 16:00:00 美东时间
100.47
+2.240
+2.28%
華盛通- 最 高101.079
- 今 開100.02
- 成交量 58.87万股
- 最 低 97.49
- 昨 收 98.23
- 總市值 60.16亿
- 52周最高 105.74
- 市盈率 靜 --
- 換手率 0.98%
- 52周最低 36.8801
- 委 比 -81.82%
- 總股本 5988.00万
- 歷史最高 105.74
- 量 比 0.73
- 振 幅 3.65%
- 歷史最低 6.513
- 每 手 1
- 風險率 16.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mirum Pharmaceuticals Gets Health Canada Authorization For LIVMARLI Oral Solution, Tablet Formulation To Treat Cholestatic Pruritus
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and tablet formulation for the treatment of
02-05 21:13
Top 3 Health Care Stocks That May Implode In Q1
As of Feb. 2, 2026, three stocks in the health care sector could be flashing a ...
02-02 18:29
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
Mirum Pharmaceuticals CEO Christopher Peetz Reports Disposal of Common Shares
Mirum Pharmaceuticals CEO Christopher Peetz Reports Disposal of Common Shares Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was cre
01-28 05:30
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding the late-stage investigational therapy brelovitug for chronic hepatitis delta virus (HDV) to its portfolio. Brelovitug, a fully human monoclonal ant
01-26 21:00
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $102 to $130.
01-26 20:09
U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies
U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies Jan 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CACI International, First Citizens Bancshares and Teledyne Technologies, o
01-26 15:22
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Enthorin Therapeutics' Licensing Partner, Mirum Pharmaceuticals, Announces Initiation Of BLOOM Phase 2 Clinical Study Evaluating MRM-3379 In Fragile X Syndrome
Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner forMRM-3379(formerly ENT-3379), Mirum
01-10 00:57
